News2 The transition from an R&D company into a commercial entity in the life sciences industry is always a challenging endeavour, but we believe Prometic's unique drug discovery platforms and promising drug candidates such as Ryplazim [TM] (plasminogen) and PBI-4050 have the potential to successfully address serious and large unmet medical needs," said Stefan Clulow, Managing Director and Chief Investment Officer of Thomvest Asset Management Inc. "We remain convinced that with the right strategic focus and financial support, Prometic possesses all the necessary elements to become a leading force globally in the field of rare and orphan diseases."